Zecs you’re not informed correctly because you do no research. Phase 1a was done to move towards phase 2a which is a faster and cheaper root for the company as the CEO stated they will move to licence the drug for cardiovascular indication and follow Walter Reed and US defence force for TBI because they will be taking non dilutive funding
Your 1-2 years is 6 months away from first patient for phase 2a and not 1-2 years for results majority of phase 2a take 6 months lol with enough funding for results on Phase 2a. You are one of a kind Zecs but don’t follow the company at all
And why do you think AGN is a 110 million market cap for the past 2 years and only completing phase 1? Because NA-1 proved the concept in humans. NYR main mechanism of action follows the other two. Hence it will be valued at a 100 million dollar plus market cap and even if they raise 3-4 million until they get licensing after phase 2a market share price going a lot higher.
Some licensing deals are worth 100-500 million dollars. Let’s see what happens
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)